Our principal, Ms. Pauli Wong, was invited by HKUST to speak at their Entrepreneurship 101 Training Program on the topic of protecting start-ups through intellectual property. Her talk, titled “Patent 101 for Entrepreneurs and Start-Ups,” covered the fundamentals of IP, with a particular focus on patents. She highlighted often-overlooked aspects and shared invaluable tips to help start-up entrepreneurs avoid common pitfalls.

Pauli really enjoyed giving the talk and felt inspired by the positive feedback from the audience. She found it rewarding to share her knowledge about intellectual property and its importance for entrepreneurs. This experience has motivated her to give more presentations in the future, as she wants to reach more people and help them understand IP better.

On a side note, we want to wish the HKUST Entrepreneurship Center a happy 25th anniversary, which they are celebrating this week!




Our Past Events

Recommended Insights

China Top 10 Patent Re-Examination and Invalidation Cases of 2020 CNIPA Upholds Bayer’s Rivaroxaban Patent

9 June 2021
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

12 December 2023
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]

Breaking: China Released New Implementation Measures for the New Patent Linkage System

14 July 2021
On July 4, 2021, China’s National Medical Products Administration (NMPA) and the China National Intellectual Property Administration (CNIPA) released details on the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage”), effective July 4, 2021. Below is a summary highlighting key provisions and changes from the draft measures. Creation of an […]

The Latest on Post-Filing Data in China’s Patent Law

29 April 2020
Post-filing data can sometimes be the crucial difference between a patent allowance and a final rejection. The reasons are endless why important data may not have been included in the original patent application as filed. Time and budget may have been insufficient to generate data over the full scope of the claims at the time […]
Top crossarrow-right